0001209191-21-025841.txt : 20210407
0001209191-21-025841.hdr.sgml : 20210407
20210407160419
ACCESSION NUMBER: 0001209191-21-025841
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210405
FILED AS OF DATE: 20210407
DATE AS OF CHANGE: 20210407
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sanna Bastiano
CENTRAL INDEX KEY: 0001829069
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 21812110
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-04-05
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001829069
Sanna Bastiano
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP, Cell & Genetic Therapies
Common Stock
2021-04-05
4
S
0
1297
213.89
D
36223
D
Common Stock
2021-04-05
4
S
0
389
214.99
D
35834
D
Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $213.89 (range $213.40 to $214.25).
Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $214.99 (range $214.76 to $215.20).
/s/ Sabrina Yohai, Attorney-in-Fact
2021-04-07